tafinlar
Generic: dabrafenib
Labeler: novartis pharmaceuticals corporationDrug Facts
Product Profile
Brand Name
tafinlar
Generic Name
dabrafenib
Labeler
novartis pharmaceuticals corporation
Dosage Form
TABLET, FOR SUSPENSION
Routes
Active Ingredients
dabrafenib mesylate 10 mg/1
Manufacturer
Identifiers & Regulatory
Product NDC
0078-1154
Product ID
0078-1154_27e1701b-e920-49fc-a56f-46b2d23a8271
Product Type
HUMAN PRESCRIPTION DRUG
Marketing Category
NDA
Application Number
NDA217514
Listing Expiration
2026-12-31
Marketing Start
2023-03-16
Pharmacologic Class
Classes
Normalized Code Variants
Searchable formats for this product NDC code
Digits Only
00781154
Hyphenated Format
0078-1154
Supplemental Identifiers
RxCUI
UNII
Packaging Origin
Original Packager
Resolved Product View
Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.
Resolved Identity
Brand Name
tafinlar (source: ndc)
Generic Name
dabrafenib (source: ndc)
Application Number
NDA217514 (source: ndc)
Routes
source: ndc
Resolved Composition
Strengths
- 10 mg/1
Packaging
- 210 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-1154-21)
Packages (1)
Ingredients (1)
Linked Drug Pages (1)
Raw FDA Data
View complete raw FDA NDC JSON payload
{"route": ["ORAL"], "spl_id": "27e1701b-e920-49fc-a56f-46b2d23a8271", "openfda": {"unii": ["B6DC89I63E"], "rxcui": ["1424916", "1424918", "1425228", "1425230", "2632552", "2632556"], "spl_set_id": ["fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea"], "manufacturer_name": ["Novartis Pharmaceuticals Corporation"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "210 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-1154-21)", "package_ndc": "0078-1154-21", "marketing_start_date": "20230316"}], "brand_name": "Tafinlar", "product_id": "0078-1154_27e1701b-e920-49fc-a56f-46b2d23a8271", "dosage_form": "TABLET, FOR SUSPENSION", "pharm_class": ["Breast Cancer Resistance Protein Inhibitors [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C19 Inducers [MoA]", "Cytochrome P450 2C8 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 3A4 Inducers [MoA]", "Kinase Inhibitor [EPC]", "Organic Anion Transporter 1 Inhibitors [MoA]", "Organic Anion Transporter 3 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]", "Protein Kinase Inhibitors [MoA]"], "product_ndc": "0078-1154", "generic_name": "dabrafenib", "labeler_name": "Novartis Pharmaceuticals Corporation", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Tafinlar", "active_ingredients": [{"name": "DABRAFENIB MESYLATE", "strength": "10 mg/1"}], "application_number": "NDA217514", "marketing_category": "NDA", "marketing_start_date": "20230316", "listing_expiration_date": "20261231"}